1
|
López de Sa A, Pascual A, Garcia Santos J, Mendez R, Bellon M, Ramirez M, Matute F, Del Arco C, Manzano A, Coronado P, Casado A, Marquina G. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol 2021; 19:331. [PMID: 34801049 PMCID: PMC8606074 DOI: 10.1186/s12957-021-02438-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 11/01/2021] [Indexed: 11/16/2022] Open
Abstract
Background Inflammatory myofibroblastic tumour is an infrequent mesenchymal neoplasia of unknown aetiology and variable behaviour, ranging from rather benign lesions to locally aggressive and even metastatic disease. Its presence has been described in almost all organs; however, its location in the female genital tract has rarely been reported. Case presentation We present the case of a 47-year-old female, who was studied in our institution for a recent medical history of several weeks of dyspareunia and abdominal pain. She underwent pertinent studies including ultrasonography and CT scan. Under suspicion of degenerated leiomyoma, a total hysterectomy was performed. Unexpectedly, the pathological study of the surgical specimen showed very few tumour cells with focal fusiform morphology surrounded by an abundant inflammatory infiltrate; a thorough immunohistochemistry study lead to myofibroblastic tumour of the cervix diagnosis. A PET-CT scan did not show metastatic disease. The patient did not undergo any adjuvant treatment, and she is currently on surveillance with no evidence of disease relapse. Conclusions Inflammatory myofibroblastic tumour remains a rare entity yet to be fully elucidated. The diagnosis is based on pathological study due to the lack of typical clinical manifestations and typical radiological images. Surgical resection is the most frequent treatment, whereas chemotherapy and radiotherapy are restricted to locally advanced or metastatic disease. Tirosine kinase inhibitor crizotinib has shown promising results especially in tumours harbouring ALK mutation.
Collapse
Affiliation(s)
- Alfonso López de Sa
- Department of Medical Oncology, Hospital Clinico san Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Alejandro Pascual
- Department of Pathology, Hospital Universitario Clinico San Carlos, Madrid, Spain
| | - Javier Garcia Santos
- Gynaecologic Oncology Unit, Hospital Clinico san Carlos, Department of Obstetrics and Gynaecology, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Ramiro Mendez
- Department of Radiology, Hospital Clinico san Carlos, Department of Radiology and Physics Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Monica Bellon
- Gynaecologic Oncology Unit, Hospital Clinico san Carlos, Department of Obstetrics and Gynaecology, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Mar Ramirez
- Gynaecologic Oncology Unit, Hospital Clinico san Carlos, Department of Obstetrics and Gynaecology, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Fatima Matute
- Department of Radiology, Hospital Clinico san Carlos, Department of Radiology and Physics Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Cristina Del Arco
- Department of Pathology, Hospital Universitario Clinico San Carlos, Madrid, Spain
| | - Aránzazu Manzano
- Department of Medical Oncology, Hospital Clinico san Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Pluvio Coronado
- Gynaecologic Oncology Unit, Hospital Clinico san Carlos, Department of Obstetrics and Gynaecology, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Antonio Casado
- Department of Medical Oncology, Hospital Clinico san Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain
| | - Gloria Marquina
- Department of Medical Oncology, Hospital Clinico san Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain.
| |
Collapse
|